REVENUE (Tables)

3 Months Ended

Mar. 31, 2025

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

The following table summarizes the disaggregation of revenue by nature:

	Three Months Ended March 31,
Dollars in millions	2025		2024
Net product sales	$	10,886	$	11,559
Alliance revenues	88		134
Other revenues	227		172
Total Revenues	$	11,201	$	11,865

Revenue Recognition Gross-To-Net Adjustments

The following table summarizes GTN adjustments:

	Three Months Ended March 31,
Dollars in millions	2025		2024
Gross product sales	$	19,874	$	19,295
GTN adjustments(a)
Charge-backs and cash discounts	(2,958)		(2,556)
Medicaid and Medicare rebates	(3,840)		(3,084)
Other rebates, returns, discounts and adjustments	(2,190)		(2,096)
Total GTN adjustments(b)	(8,988)		(7,736)
Net product sales	$	10,886	$	11,559

(a)    Includes reductions to GTN adjustments for product sales made in prior periods resulting from changes in estimates of $289 million and $80 million for the three months ended March 31, 2025 and 2024, respectively.

(b)    Includes U.S. GTN adjustments of $8.2 billion and $6.9 billion for the three months ended March 31, 2025 and 2024, respectively.

Revenue from External Customers by Products and Services

The following table summarizes the disaggregation of revenue by product and region:

	Three Months Ended March 31,
Dollars in millions	2025		2024
Growth Portfolio
Opdivo	$	2,265	$	2,078
Opdivo Qvantig	9		—
Orencia	770		798
Yervoy	624		583
Reblozyl	478		354
Opdualag	252		206
Breyanzi	263		107
Camzyos	159		84
Zeposia	107		110
Abecma	103		82
Sotyktu	55		44
Krazati	48		21
Cobenfy	27		—
Other Growth products(a)	403		325
Total Growth Portfolio	5,563		4,792
Legacy Portfolio
Eliquis	3,565		3,720
Revlimid	936		1,669
Pomalyst/Imnovid	658		865
Sprycel	175		374
Abraxane	105		217
Other Legacy products(b)	199		228
Total Legacy Portfolio	5,638		7,073
Total Revenues	$	11,201	$	11,865
United States	$	7,873	$	8,476
International(c)	3,110		3,190
Other(d)	218		199
Total Revenues	$	11,201	$	11,865

(a)    Includes Augtyro, Onureg, Inrebic, Nulojix, Empliciti and royalty revenues.

(b)    Includes other mature brands.

(c)     Includes Puerto Rico.    

(d)    Other revenues include alliance-related revenues for products not sold by BMS's regional commercial organizations.